Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories company, and gene therapy company CombiGene AB, have completed the production and quality assurance of the plasmids to be used in the GMP production of CG01, for CombiGene’s gene therapy for the treatment of drug-resistant focal epilepsy.   The now released GMP plasmids were produced by Cobra in January/February this year. The material has since been quality assured through a variety of analyses. Thes...